ArticleNature medicine2024
An autoantibody signature predictive for multiple sclerosis.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
28.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions.International journal of molecular sciences · 2025Pooled it
- Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology.The Journal of clinical investigation · 2025Trial
- Associations of viral infections and antiviral vaccinations with anti-NMDAR and other forms of autoimmune encephalitis.Brain, behavior, & immunity - health · 2026Review
- Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.Cell death and differentiation · 2026Review
- Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.JAMA neurology · 2026Article
- Article
- Biomarkers in Clinical Medicine Research: A Literature Survey in the PubMed Database and a Critical Evaluation.Journal of clinical medicine · 2026Review
- Predicting health and disease: a conceptual framework for AI in preventive and precision medicine.BMJ health & care informatics · 2026Review
- Infectious Agents in Multiple Sclerosis: Viral Triggers, Antibody-Mediated Autoimmunity, and Parasitic Immunomodulation.Biomolecules · 2026Review
- Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity.International journal of molecular sciences · 2026Article
- Increased VH4+JH6+ antibody heavy chain use in plasmablasts from asymptomatic multiple sclerosis patients.Genes and immunity · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Antibody Profiles in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.bioRxiv : the preprint server for biology · 2026Article
- Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Why Is MS a More Frequent Complication of EBV Infection in Females?Immunological reviews · 2026Review
- Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity.medRxiv : the preprint server for health sciences · 2026Article
- An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.Journal of neurology · 2026Article
- Immune profiling links autoimmune hepatitis to human herpesvirus 6 and relaxin receptor antigens.The Journal of experimental medicine · 2026Article
- Towards primary prevention of multiple sclerosis.Nature reviews. Neurology · 2026Review
Corrections and comments
- Update of
Authors and funding
41 authors at 4 institutions in 1 country.
Colin R Zamecnik *Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9477-1388
Gavin M Sowa *University of California, San Francisco School of Medicine, San Francisco, CA, USA.ORCID 0000-0002-2089-8116
Ahmed AbdelhakDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Ravi DandekarDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Rebecca D BairDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Kristen J WadeDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Christopher M BartleyDepartment of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1391-4130
Kerry KizerDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Danillo G AugustoDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Asritha TubatiDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Refujia GomezDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Camille FouassierDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Chloe GerunganDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Colette M CasparDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Jessica AlexanderDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Anne E WapniarskiDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Rita P LoudermilkDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9970-5112
Erica L EggersDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Kelsey C ZornDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1227-2137
Kirtana AnanthDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Nora JabassiniDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Sabrina A MannDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Nicholas R RaganDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Adam SantanielloDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Roland G HenryDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Sergio E BaranziniDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0067-194X
Scott S ZamvilDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2720-9915
Joseph J SabatinoDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6804-7441
Riley M BoveDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2034-8800
Chu-Yueh GuoDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Jeffrey M GelfandDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Richard CuneoDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
H-Christian von BüdingenDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Jorge R OksenbergDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Bruce A C CreeDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Jill A HollenbachDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6572-7962
Ari J GreenDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Stephen L HauserDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4932-4001
Mitchell T WallinDepartment of Veterans Affairs, Multiple Sclerosis Center of Excellence, Washington, DC, USA.
Joseph L DeRisiDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Michael R WilsonDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. michael.wilson@ucsf.edu.ORCID 0000-0002-8705-5084
University of California, San Francisco · USNorthwestern University · USUniversity of Maryland, Baltimore · USUniversity of North Carolina at Charlotte · US
Funding
The Role of B cells in the Origin and Progression of Multiple SclerosisR35NS111644 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEPHEN L HAUSER · 2019 to 2026
$9.1MThe Molecular Architecture of Axons in Health and DiseaseR35NS122073 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW N RASBAND · 2021 to 2026
$5.6MThe landscape of HLA mediated variation in health and immunityR01AI158861 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLLENBACH, JILL ALLISON · 2021 to 2025
$3.5MCharacterization of T cells in MOG antibody-associated diseaseR01AI170863 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCOTT S ZAMVIL · 2023 to 2026
$3.2MRole of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease CourseR01AI169070 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, Paul John Norman · 2022 to 2026
$3.0MNational Multiple Sclerosis Society (National MS Society) RFA-2104-3747National Multiple Sclerosis Society (National MS Society) RFA-2104-37504NIAID NIH HHS R01 AI158861NIAID NIH HHS R01 AI169070NIAID NIH HHS R01 AI170863NINDS NIH HHS R35 NS111644NINDS NIH HHS R35 NS122073U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI158861U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R35NS122073
Abstract
Although B cells are implicated in multiple sclerosis (MS) pathophysiology, a predictive or diagnostic autoantibody remains elusive. In this study, the Department of Defense Serum Repository (DoDSR), a cohort of over 10 million individuals, was used to generate whole-proteome autoantibody profiles of hundreds of patients with MS (PwMS) years before and subsequently after MS onset. This analysis defines a unique cluster in approximately 10% of PwMS who share an autoantibody signature against a common motif that has similarity with many human pathogens. These patients exhibit antibody reactivity years before developing MS symptoms and have higher levels of serum neurofilament light (sNfL) compared to other PwMS. Furthermore, this profile is preserved over time, providing molecular evidence for an immunologically active preclinical period years before clinical onset. This autoantibody reactivity was validated in samples from a separate incident MS cohort in both cerebrospinal fluid and serum, where it is highly specific for patients eventually diagnosed with MS. This signature is a starting point for further immunological characterization of this MS patient subset and may be clinically useful as an antigen-specific biomarker for high-risk patients with clinically or radiologically isolated neuroinflammatory syndromes.
Indexed as
AutoantibodiesMultiple SclerosisNeurofilament ProteinsAdultBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedAutoantibodiesBiomarkersneurofilament protein LNeurofilament Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.